{
    "root": "502b3505-5c28-4d75-9d5e-c96d84a19224",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clarithromycin",
    "value": "20240328",
    "ingredients": [
        {
            "name": "CLARITHROMYCIN",
            "code": "H1250JIK0A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3732"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "VANILLIN",
            "code": "CHI530446X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_18346"
        },
        {
            "name": "SORBIC ACID",
            "code": "X045WJ989B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_35962"
        }
    ],
    "indications": {
        "text": "clarithromycin tablets macrolide antimicrobial indicated mild moderate infections caused designated , susceptible bacteria following : \u2022 acute bacterial exacerbation chronic bronchitis adults ( 1.1 ) \u2022 acute maxillary sinusitis ( 1.2 ) \u2022 community-acquired pneumonia ( 1.3 ) \u2022 pharyngitis/tonsillitis ( 1.4 ) \u2022 uncomplicated skin skin structure infections ( 1.5 ) \u2022 acute otitis media pediatric patients ( 1.6 ) \u2022 treatment prophylaxis disseminated mycobacterial infections ( 1.7 ) \u2022 helicobacter pylori infection duodenal ulcer disease adults ( 1.8 ) limitations reduce development drug-resistant bacteria maintain effectiveness clarithromycin tablets antibacterial drugs , clarithromycin tablets used treat prevent infections proven strongly suspected caused bacteria . ( 1.9 )",
        "doid_entities": [
            {
                "text": "chronic bronchitis (DOID:6132)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6132"
            },
            {
                "text": "acute maxillary sinusitis (DOID:2050)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2050"
            },
            {
                "text": "maxillary sinusitis (DOID:2051)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2051"
            },
            {
                "text": "sinusitis (DOID:0050127)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050127"
            },
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            },
            {
                "text": "otitis media (DOID:10754)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10754"
            },
            {
                "text": "helicobacter pylori infection (DOID:3686)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3686"
            },
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "acute otitis media",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_279888"
            },
            {
                "disease": "chronic bronchitis adults",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_98255"
            }
        ]
    },
    "contraindications": {
        "text": "\u2022 adults : clarithromycin tablets 250 mg 500 mg every 12 hours 7 14 days ( 2.2 ) \u2022 h. pylori eradication ( combination lansoprazole/amoxicillin , omeprazole/amoxicillin , omeprazole ) : clarithromycin tablets 500 mg every 8 12 hours 10 14 days . full prescribing information ( fpi ) additional information . ( 2.3 ) \u2022 pediatric patients : clarithromycin tablets 15 mg/kg/day divided every 12 hours 10 days ( 2.4 ) \u2022 mycobacterial infections : clarithromycin tablets 500 mg every 12 hours ; clarithromycin tablets 7.5 mg/kg 500 mg every 12 hours pediatric patients ( 2.5 ) \u2022 reduce dose moderate renal impairment concomitant atazanavir ritonavir-containing regimens severe renal impairment ( 2.6 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "clarithromycin tablets usp , 500 mg light yellow colored , oval shaped , biconvex film-coated tablets , \u2018 \u2019 debossed one side \u2018 63 \u2019 side . bottles 20 ndc 68788-8480-2bottles 30 ndc 68788-8480-3 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "\u2022 hypersensitivity clarithromycin macrolide ( 4.1 ) \u2022 cisapride pimozide ( 4.2 ) \u2022 history cholestatic jaundice/hepatic dysfunction clarithromycin ( 4.3 ) \u2022 colchicine renal hepatic impairment ( 4.4 ) \u2022 lomitapide , lovastatin , simvastatin ( 4.5 ) \u2022 ergot alkaloids ( ergotamine dihydroergotamine ) ( 4.6 ) \u2022 lurasidone ( 4.7 )",
    "indications_original": "Clarithromycin tablets are a macrolide antimicrobial indicated for mild to moderate infections caused by designated, susceptible bacteria in the following: \u2022 Acute Bacterial Exacerbation of Chronic Bronchitis in Adults ( 1.1 ) \u2022 Acute Maxillary Sinusitis ( 1.2 ) \u2022 Community-Acquired Pneumonia ( 1.3 ) \u2022 Pharyngitis/Tonsillitis ( 1.4 ) \u2022 Uncomplicated Skin and Skin Structure Infections ( 1.5 ) \u2022 Acute Otitis Media in Pediatric Patients ( 1.6 ) \u2022 Treatment and Prophylaxis of Disseminated Mycobacterial Infections ( 1.7 ) \u2022 Helicobacter pylori Infection and Duodenal Ulcer Disease in Adults ( 1.8 ) Limitations of Use To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.9 )",
    "contraindications_original": "\u2022 Adults: Clarithromycin tablets 250 mg or 500 mg every 12 hours for 7 to 14 days ( 2.2 ) \u2022 H. pylori eradication (in combination with lansoprazole/amoxicillin, omeprazole/amoxicillin, or omeprazole): Clarithromycin tablets 500 mg every 8 or 12 hours for 10 to 14 days. See full prescribing information (FPI) for additional information. ( 2.3 ) \u2022 Pediatric Patients: Clarithromycin tablets\u00a015 mg/kg/day divided every 12 hours for 10 days ( 2.4 ) \u2022 Mycobacterial Infections: Clarithromycin tablets 500 mg every 12 hours; clarithromycin tablets 7.5 mg/kg up to 500 mg every 12 hours in pediatric patients ( 2.5 ) \u2022 Reduce dose in moderate renal impairment with concomitant atazanavir or ritonavir-containing regimens and in severe renal impairment ( 2.6 )",
    "warningsAndPrecautions_original": "Clarithromycin Tablets USP, 500 mg are light yellow colored, oval shaped, biconvex film-coated tablets, with \u2018D\u2019 debossed on one side and \u201863\u2019 on the other side.\n                  Bottles of 20\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 68788-8480-2Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0NDC 68788-8480-3\n                  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F)\u00a0[see USP Controlled Room Temperature].",
    "adverseReactions_original": "\u2022 Hypersensitivity to clarithromycin or any macrolide drug ( 4.1 ) \u2022 Cisapride and pimozide ( 4.2 ) \u2022 History of cholestatic jaundice/hepatic dysfunction with use of clarithromycin ( 4.3 ) \u2022 Colchicine in renal or hepatic impairment ( 4.4 ) \u2022 Lomitapide, lovastatin, and simvastatin ( 4.5 ) \u2022 Ergot alkaloids (ergotamine or dihydroergotamine) ( 4.6 ) \u2022 Lurasidone ( 4.7 )",
    "drug": [
        {
            "name": "Clarithromycin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3732"
        }
    ]
}